ACP
CNCE

Acuta Capital Partners’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Acuta Capital Partners’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-537,500
Closed -$6.79M – 62
2020
Q4 		$6.79M Buy
537,500
+237,500
+79% +$2.71M 1.85% 22
2020
Q3 		$2.95M Buy
+300,000
New +$2.96M 0.8% 36
2017
Q2 		– Sell
-49,051
Closed -$837K – 80
2017
Q1 		$837K Buy
+49,051
New +$588K 0.2% 57

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acuta Capital Partners's CNCE Position: Q1 2021 in Review

Acuta Capital Partners sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2021, closing a stake of 537,500 shares — an estimated $6.79M sold.

Acuta Capital Partners first reported a position in CNCE in Q1 2017 and held it in 3 quarters. The position peaked at $6.79M in Q4 2020. 91 funds tracked by Wall St. Rank hold CNCE as of Q1 2021.

  • Acuta Capital Partners reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Acuta Capital Partners sold 537,500 Concert Pharmaceuticals, Inc. shares in Q1 2021, an estimated $6.79M.
  • Acuta Capital Partners first reported a position in Concert Pharmaceuticals, Inc. in Q1 2017 and held it in 3 quarters.
  • Acuta Capital Partners's Concert Pharmaceuticals, Inc. position peaked at $6.79M in Q4 2020.
  • 91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2021.

Based on Acuta Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.